ASX:RMD Archives - Investor Signals

Resmed

ResMed is due to report 4Q23E EPS Friday.

ResMed is due to report 4Q23E EPS Friday.

ResMed is under Algo Engine buy conditions.

ResMed is approaching a price range where we’re likely to see a new Algo Engine buy condition.

ResMed is under Algo Engine buy conditions and we see buying support building within the $30 – $33 price range.

ResMed is under Algo Engine buy conditions and we see buying support building.

ResMed is under Algo Engine buy conditions and is now up 84% since being added to our model in October 2018.

RMD delivered a solid earnings result and upgrades to earnings are partially offset by the stronger AUD.

RMD is looking to resume share buybacks in 2H21.

We see buying support at $26 and suggest investors look to accumulate the stock.